Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
JAJaguar Health, Inc. logo

Jaguar Health, Inc. (JAGX)

NASDAQ Capital Market · Currency in USD
$2.04 ▼ -0.11 (-5.12%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.03 ▼ -0.01 (-0.49%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$2.15
Open
$2.05
Day's Range
$2.03 – $2.06
52 Week Range
$2.03 – $1,118.25
Volume
130,109
Avg. Volume
1,422,045
Market Cap
$3.97M
Beta (5Y Monthly)
-0.06
PE Ratio (TTM)
--
EPS (TTM)
-$679.41
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.21

Profile: Jaguar Health, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
47
CEO
Lisa A. Conte

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$444.29 · Revenue est. $4.85M
DateEst.Actual
Aug 19, 2026-$565.81-$235.38Beat
May 20, 2026-$10.71-$2.04Beat
Apr 7, 2026-$1.49-$3.14Miss
Nov 12, 2025-$1.78-$2.20Miss
Aug 14, 2025-$2.50-$3.59Miss
May 15, 2025-$3.79-$5.85Miss

Analyst view

Consensus price target
$3.21 ▲ +57.4%
Range $3.21 – $3.21
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on JAGX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.